Argus Research Downgrades Elevance Health from Buy to Hold.
ByAinvest
Monday, Jul 21, 2025 9:06 am ET1min read
ELV--
Elevance Health's President and CEO, Gail Boudreaux, recently purchased shares of the company's stock totaling $2.4 million, indicating a level of confidence in the company's future despite the current market conditions [1]. The insider buying, however, did not prevent Argus Research from expressing caution about the company's ability to navigate the volatile healthcare landscape.
The downgrade follows a series of adjustments and evaluations following Elevance's second-quarter earnings report. The company reported earnings per share of $8.84, a 12.6% decline year-over-year and $0.14 below consensus estimates. This prompted several analysts to lower their price targets and ratings. Guggenheim, for instance, reduced its price target to $360 while maintaining a Buy rating, citing cost pressures in Medicaid and the Health Insurance Exchange market [2].
Elevance Health's full-year 2025 earnings per share guidance was also revised downward to $30, down from its previous range of $34.15 to $34.85. This reduction in guidance reflects the company's struggle with elevated medical cost trends and slower Medicaid rate alignment. The sector-wide challenges, including membership losses and reimbursement pressures, have led to a significant decline in the stock's valuation. Since April, more than $300 billion in market capitalization has been wiped out from the healthcare sector [3].
Despite these challenges, Elevance Health continues to explore growth opportunities, particularly in Medicare Advantage and value-based care. The company's expansion into these segments could potentially offset some of the current pressures. However, the road ahead remains uncertain, and investors are advised to closely monitor the company's performance and policy developments.
References:
[1] https://m.au.investing.com/news/insider-trading-news/elevance-health-ceo-boudreaux-buys-24-million-in-stock-93CH-3933316?ampMode=1
[2] https://www.gurufocus.com/news/2987632/elevance-health-elv-target-price-reduced-amid-earnings-guidance-concerns-elv-stock-news
[3] https://www.marketscreener.com/news/elevance-health-the-big-hit-ce7c5cdfd18bf12d
Argus Research Downgrades Elevance Health from Buy to Hold.
In a significant development for the healthcare sector, Argus Research has downgraded Elevance Health (NYSE: ELV) from a "Buy" rating to a "Hold" rating, citing concerns over the company's financial outlook and recent earnings reports. The move comes as the healthcare giant faces a challenging environment marked by elevated medical costs, regulatory pressures, and uncertain policy changes.Elevance Health's President and CEO, Gail Boudreaux, recently purchased shares of the company's stock totaling $2.4 million, indicating a level of confidence in the company's future despite the current market conditions [1]. The insider buying, however, did not prevent Argus Research from expressing caution about the company's ability to navigate the volatile healthcare landscape.
The downgrade follows a series of adjustments and evaluations following Elevance's second-quarter earnings report. The company reported earnings per share of $8.84, a 12.6% decline year-over-year and $0.14 below consensus estimates. This prompted several analysts to lower their price targets and ratings. Guggenheim, for instance, reduced its price target to $360 while maintaining a Buy rating, citing cost pressures in Medicaid and the Health Insurance Exchange market [2].
Elevance Health's full-year 2025 earnings per share guidance was also revised downward to $30, down from its previous range of $34.15 to $34.85. This reduction in guidance reflects the company's struggle with elevated medical cost trends and slower Medicaid rate alignment. The sector-wide challenges, including membership losses and reimbursement pressures, have led to a significant decline in the stock's valuation. Since April, more than $300 billion in market capitalization has been wiped out from the healthcare sector [3].
Despite these challenges, Elevance Health continues to explore growth opportunities, particularly in Medicare Advantage and value-based care. The company's expansion into these segments could potentially offset some of the current pressures. However, the road ahead remains uncertain, and investors are advised to closely monitor the company's performance and policy developments.
References:
[1] https://m.au.investing.com/news/insider-trading-news/elevance-health-ceo-boudreaux-buys-24-million-in-stock-93CH-3933316?ampMode=1
[2] https://www.gurufocus.com/news/2987632/elevance-health-elv-target-price-reduced-amid-earnings-guidance-concerns-elv-stock-news
[3] https://www.marketscreener.com/news/elevance-health-the-big-hit-ce7c5cdfd18bf12d
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet